CJC-1295 (Without DAC) | GHRH Analogue

Research Overview

CJC-1295 (without DAC) is a synthetic analogue of growth hormone releasing hormone (GHRH), a 29-amino acid peptide. Without the Drug Affinity Complex (DAC), it has a shorter half-life and is studied for its pulsatile stimulation of growth hormone release.

Published research has examined CJC-1295’s ability to stimulate GH and IGF-1 secretion in animal models, its synergistic effects when combined with GHRP compounds such as Ipamorelin, and its half-life characteristics relative to endogenous GHRH. Studies have investigated applications in models of GH deficiency and age-related hormonal decline.

Select Published Research

Teichman SL et al. (2006). “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295.” Journal of Clinical Endocrinology & Metabolism.
Alba M et al. (2006). “Once-monthly administration of CJC-1295.” Journal of Clinical Endocrinology & Metabolism.

All referenced studies were conducted in human or animal subjects in controlled clinical or research settings. These citations do not constitute claims of safety or efficacy for unsupervised use.

Specifications

Format: Lyophilized powder
Purity: >99% verified by HPLC and mass spectrometry
Storage: −20°C lyophilized. Reconstituted: 4°C, use within 30 days.
Source: Domestically synthesized

Certificate of Analysis

Third-party COA available in the Lab Results tab above.